Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RYTM Stock Forecast

Rhythm Pharmaceuticals stock forecast is as follows: an average price target of $64.50 (represents a 14.93% upside from RYTM’s last price of $56.12) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

RYTM Price Target

The average price target for Rhythm Pharmaceuticals (RYTM) is $64.50 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $64.00. This represents a potential 14.93% upside from RYTM's last price of $56.12.

RYTM Analyst Ratings

Buy

According to 9 Wall Street analysts, Rhythm Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RYTM stock is 0 'Strong Buy' (0.00%), 9 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rhythm Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 05, 2024	Corinne Jenkins	Goldman Sachs	$66.00	$60.02	9.97%	17.61%
Nov 06, 2024	Alan Carr	Needham	$64.00	$55.78	14.73%	14.04%
Nov 06, 2024	Corinne Jenkins	Goldman Sachs	$59.00	$55.78	5.76%	5.13%
Sep 18, 2024	Raghuram Selvaraju	H.C. Wainwright	$64.00	$53.17	20.37%	14.04%
Sep 17, 2024	Jonathan Wolleben	JMP Securities	$64.00	$54.00	18.52%	14.04%
Jul 25, 2024	Alan Carr	Needham	$55.00	$49.61	10.86%	-2.00%
Nov 10, 2022		Goldman Sachs	$35.00	$24.68	41.82%	-37.63%
Aug 07, 2022	Corinne Jenkins	Goldman Sachs	$28.00	$20.24	38.34%	-50.11%
Jul 12, 2022	Corinne Jenkins	Goldman Sachs	$6.00	$6.38	-5.96%	-89.31%
Jun 17, 2022		Needham	$25.00	$3.90	541.03%	-55.45%
Jun 17, 2022	Dae Gon Ha	Stifel Nicolaus	$25.00	$3.90	541.03%	-55.45%

The latest Rhythm Pharmaceuticals stock forecast, released on Dec 05, 2024 by Corinne Jenkins from Goldman Sachs, set a price target of $66.00, which represents a 9.97% increase from the stock price at the time of the forecast ($60.02), and a 17.61% increase from RYTM last price ($56.12).

Rhythm Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	1	4	6
Avg Price Target	$66.00	$63.25	$62.00
Last Closing Price	$56.12	$56.12	$56.12
Upside/Downside	17.61%	12.70%	10.48%

In the current month, the average price target of Rhythm Pharmaceuticals stock is $66.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 17.61% increase as opposed to Rhythm Pharmaceuticals's last price of $56.12. This month's average price target is up 4.35% compared to last quarter, and up 6.45% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 05, 2024	Goldman Sachs	Buy	Buy	Hold
Nov 06, 2024	Cowen & Co.	Buy	Buy	Hold
Nov 06, 2024	Goldman Sachs	Buy	Buy	Hold
Oct 21, 2024	Guggenheim		Buy	Initialise
Sep 18, 2024	Needham	Market Outperform	Market Outperform	Hold
Sep 18, 2024	H.C. Wainwright		Buy	Initialise
Sep 17, 2024	JMP Securities		Outperform	Initialise
Sep 17, 2024	JMP Securities		Market Outperform	Initialise
Jul 25, 2024	Needham	Buy	Buy	Hold
Feb 22, 2024	Wells Fargo	Buy	Buy	Hold
Dec 19, 2023	Morgan Stanley	Equal-Weight	Overweight	Upgrade
Oct 10, 2023	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Aug 01, 2023	Bank of America Securities	Neutral	Buy	Upgrade
Aug 07, 2022	Goldman Sachs	Neutral	Buy	Upgrade
Aug 05, 2022	Bank of America Securities		Neutral	Upgrade
Jul 12, 2022	Goldman Sachs	Neutral	Neutral	Hold
Jun 17, 2022	Needham	Buy	Buy	Hold
Feb 25, 2022	Needham	Buy	Buy	Hold

Rhythm Pharmaceuticals's last stock rating was published by Goldman Sachs on Dec 05, 2024. The company gave RYTM a "Buy" rating, the same as its previous rate.

Rhythm Pharmaceuticals Financial Forecast

Rhythm Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	$22.50M	$19.22M	$11.47M	$8.79M	$4.28M	$9.07M	$1.50M	$1.82M	$1.03M	$274.00K	$35.00K	-	-
Avg Forecast	$52.17M	$46.23M	$42.33M	$38.10M	$36.07M	$32.52M	$28.79M	$26.90M	$25.38M	$22.18M	$15.03M	$12.12M	$7.22M	$4.76M	$2.57M	$2.30M	$1.70M	$934.20K	$551.00K	$49.90M	$60.00K	$500.00K
High Forecast	$53.46M	$47.38M	$43.38M	$38.84M	$37.79M	$32.62M	$28.79M	$26.90M	$27.26M	$23.38M	$15.40M	$12.42M	$7.40M	$4.76M	$2.57M	$2.30M	$1.70M	$934.20K	$551.00K	$49.90M	$60.00K	$500.00K
Low Forecast	$50.76M	$44.99M	$41.19M	$37.05M	$34.81M	$32.42M	$28.79M	$26.90M	$23.88M	$21.00M	$14.62M	$11.79M	$7.02M	$4.76M	$2.57M	$2.30M	$1.70M	$934.20K	$551.00K	$49.90M	$60.00K	$500.00K
# Analysts	4	4	4	6	9	4	3	4	7	8	5	4	4	3	4	3	5	4	5	4	5	4
Surprise %	-	-	-	-	-	-	-	-	-	1.01%	1.28%	0.95%	1.22%	0.90%	3.53%	0.65%	1.07%	1.10%	0.50%	0.00%	-	-

Rhythm Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $25.38M, with a low forecast of $23.88M, and a high forecast of $27.26M. RYTM's average Quarter revenue forecast represents a 12.78% increase compared to the company's last Quarter revenue of $22.50M (Sep 23).

Rhythm Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	9	4	3	4	7	8	5	4	4	3	4	3	5	4	5	4	5	4
EBITDA	-	-	-	-	-	-	-	-	-	$-40.65M	$-46.60M	$-49.12M	$-39.48M	$-38.27M	$-45.10M	$-52.34M	$-42.54M	$-43.79M	$-40.09M	$65.96M	$-34.72M	$-33.65M
Avg Forecast	$-10.43M	$-9.25M	$-8.47M	$-7.62M	$-7.21M	$-6.50M	$-5.76M	$-5.38M	$-5.08M	$-4.44M	$-3.01M	$-2.42M	$-1.44M	$-952.26K	$-513.11K	$-460.04K	$-340.43K	$-186.84K	$-110.20K	$-9.98M	$-12.00K	$-100.00K
High Forecast	$-10.15M	$-9.00M	$-8.24M	$-7.41M	$-6.96M	$-6.48M	$-5.76M	$-5.38M	$-4.78M	$-4.20M	$-2.92M	$-2.36M	$-1.40M	$-952.26K	$-513.11K	$-460.04K	$-340.43K	$-186.84K	$-110.20K	$-9.98M	$-12.00K	$-100.00K
Low Forecast	$-10.69M	$-9.48M	$-8.68M	$-7.77M	$-7.56M	$-6.52M	$-5.76M	$-5.38M	$-5.45M	$-4.68M	$-3.08M	$-2.48M	$-1.48M	$-952.26K	$-513.11K	$-460.04K	$-340.43K	$-186.84K	$-110.20K	$-9.98M	$-12.00K	$-100.00K
Surprise %	-	-	-	-	-	-	-	-	-	9.16%	15.51%	20.26%	27.35%	40.19%	87.89%	113.78%	124.96%	234.36%	363.83%	-6.61%	2893.49%	336.46%

5 analysts predict RYTM's average Quarter EBITDA for Jun 21 to be $-110.20K, with a high of $-110.20K and a low of $-110.20K. This is -100.17% lower than Rhythm Pharmaceuticals's previous annual EBITDA (Mar 21) of $65.96M.

Rhythm Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	9	4	3	4	7	8	5	4	4	3	4	3	5	4	5	4	5	4
Net Income	-	-	-	-	-	-	-	-	-	$-44.16M	$-46.70M	$-51.83M	$-42.88M	$-42.45M	$-44.91M	$-52.84M	$-42.87M	$-35.11M	$-35.39M	$43.75M	$-34.90M	$-33.82M
Avg Forecast	$-39.65M	$-42.01M	$-42.51M	$-46.45M	$-45.35M	$-49.25M	$-43.40M	$-144.25M	$-43.19M	$-45.30M	$-48.84M	$-43.93M	$-49.52M	$-60.94M	$-58.27M	$-61.83M	$-55.70M	$-49.22M	$-42.94M	$43.75M	$-48.12M	$-48.28M
High Forecast	$-38.26M	$-40.54M	$-41.02M	$-41.49M	$-25.12M	$-47.53M	$-41.88M	$-139.20M	$-40.73M	$-37.55M	$-47.13M	$-42.39M	$-47.79M	$-60.94M	$-58.27M	$-61.83M	$-55.70M	$-49.22M	$-42.94M	$52.50M	$-48.12M	$-48.28M
Low Forecast	$-40.92M	$-43.36M	$-43.88M	$-50.16M	$-63.12M	$-50.84M	$-44.79M	$-148.88M	$-47.51M	$-57.82M	$-50.41M	$-45.34M	$-51.11M	$-60.94M	$-58.27M	$-61.83M	$-55.70M	$-49.22M	$-42.94M	$35.00M	$-48.12M	$-48.28M
Surprise %	-	-	-	-	-	-	-	-	-	0.97%	0.96%	1.18%	0.87%	0.70%	0.77%	0.85%	0.77%	0.71%	0.82%	1.00%	0.73%	0.70%

Rhythm Pharmaceuticals's average Quarter net income forecast for Jun 21 is $-42.94M, with a range of $-42.94M to $-42.94M. RYTM's average Quarter net income forecast represents a -198.14% decrease compared to the company's last Quarter net income of $43.75M (Mar 21).

Rhythm Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	9	4	3	4	7	8	5	4	4	3	4	3	5	4	5	4	5	4
SG&A	-	-	-	-	-	-	-	-	-	$30.48M	$30.05M	$24.63M	$26.32M	$21.94M	$22.33M	$21.45M	$21.00M	$17.51M	$15.46M	$14.52M	$13.12M	$11.29M
Avg Forecast	$303.87M	$269.31M	$246.59M	$221.94M	$210.11M	$189.45M	$167.70M	$156.67M	$147.84M	$129.19M	$87.54M	$70.59M	$42.05M	$27.73M	$14.94M	$13.40M	$9.92M	$5.44M	$3.21M	$14.52M	$349.50K	$2.91M
High Forecast	$311.39M	$275.97M	$252.69M	$226.27M	$220.11M	$190.03M	$167.70M	$156.67M	$158.76M	$136.18M	$89.71M	$72.34M	$43.09M	$27.73M	$14.94M	$13.40M	$9.92M	$5.44M	$3.21M	$17.42M	$349.50K	$2.91M
Low Forecast	$295.70M	$262.07M	$239.96M	$215.81M	$202.79M	$188.87M	$167.70M	$156.67M	$139.10M	$122.31M	$85.19M	$68.70M	$40.92M	$27.73M	$14.94M	$13.40M	$9.92M	$5.44M	$3.21M	$11.61M	$349.50K	$2.91M
Surprise %	-	-	-	-	-	-	-	-	-	0.24%	0.34%	0.35%	0.63%	0.79%	1.49%	1.60%	2.12%	3.22%	4.82%	1.00%	37.54%	3.88%

Rhythm Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $147.84M, based on 7 Wall Street analysts, with a range of $139.10M to $158.76M. The forecast indicates a 385.12% rise compared to RYTM last annual SG&A of $30.48M (Sep 23).

Rhythm Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	6	9	4	3	4	7	8	5	4	4	3	4	3	5	4	5	4	5	4
EPS	-	-	-	-	-	-	-	-	-	$-0.76	$-0.82	$-0.91	$-0.76	$-0.83	$-0.89	$-1.05	$-0.85	$-0.70	$-0.70	$0.92	$-0.79	$-0.77
Avg Forecast	$-0.65	$-0.69	$-0.69	$-0.76	$-0.74	$-0.80	$-0.71	$-2.36	$-0.71	$-0.74	$-0.80	$-0.72	$-0.81	$-1.00	$-0.95	$-1.01	$-0.91	$-0.81	$-0.70	$0.30	$-0.79	$-0.79
High Forecast	$-0.62	$-0.66	$-0.67	$-0.68	$-0.41	$-0.78	$-0.68	$-2.27	$-0.67	$-0.61	$-0.77	$-0.69	$-0.78	$-1.00	$-0.95	$-1.01	$-0.91	$-0.81	$-0.70	$0.30	$-0.79	$-0.79
Low Forecast	$-0.67	$-0.71	$-0.72	$-0.82	$-1.03	$-0.83	$-0.73	$-2.43	$-0.78	$-0.94	$-0.82	$-0.74	$-0.83	$-1.00	$-0.95	$-1.01	$-0.91	$-0.81	$-0.70	$0.30	$-0.79	$-0.79
Surprise %	-	-	-	-	-	-	-	-	-	1.03%	1.03%	1.27%	0.94%	0.83%	0.93%	1.04%	0.93%	0.87%	0.99%	3.08%	1.00%	0.97%

According to 5 Wall Street analysts, Rhythm Pharmaceuticals's projected average Quarter EPS for Jun 21 is $-0.70, with a low estimate of $-0.70 and a high estimate of $-0.70. This represents a -176.49% decrease compared to RYTM previous annual EPS of $0.92 (Mar 21).

Rhythm Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
RCKT	Rocket Pharmaceuticals	$11.92	$42.00	252.35%	Buy
QURE	uniQure	$16.46	$53.67	226.06%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
SLDB	Solid Biosciences	$4.46	$12.00	169.06%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
KNSA	Kiniksa Pharmaceuticals	$20.49	$37.50	83.02%	Buy
RNA	Avidity Biosciences	$32.74	$59.00	80.21%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy
MGTX	MeiraGTx	$6.40	$9.00	40.63%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
NUVL	Nuvalent	$88.10	$114.80	30.31%	Buy
RYTM	Rhythm Pharmaceuticals	$56.80	$64.50	13.56%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals a good buy?

Yes, according to 9 Wall Street analysts, Rhythm Pharmaceuticals (RYTM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 100.00% of RYTM's total ratings.

What is RYTM's price target?

Rhythm Pharmaceuticals (RYTM) average price target is $64.5 with a range of $64 to $66, implying a 14.93% from its last price of $56.12. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Rhythm Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for RYTM stock, the company can go up by 14.93% (from the last price of $56.12 to the average price target of $64.5), up by 17.61% based on the highest stock price target, and up by 14.04% based on the lowest stock price target.

Can Rhythm Pharmaceuticals stock reach $80?

RYTM's average twelve months analyst stock price target of $64.5 does not support the claim that Rhythm Pharmaceuticals can reach $80 in the near future.

What is Rhythm Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $66 price target for Rhythm Pharmaceuticals (RYTM) this month, up 17.61% from its last price of $56.12. Compared to the last 3 and 12 months, the average price target increased by 12.70% and increased by 10.48%, respectively.

What are Rhythm Pharmaceuticals's analysts' financial forecasts?

Rhythm Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $124.28M (high $126.09M, low $122.92M), average EBITDA is $-24.856M (high $-24.584M, low $-25.219M), average net income is $-282M (high $-254M, low $-308M), average SG&A $723.93M (high $734.51M, low $716.03M), and average EPS is $-4.61 (high $-4.145, low $-5.025). RYTM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $178.83M (high $183.06M, low $173.99M), average EBITDA is $-35.767M (high $-34.799M, low $-36.611M), average net income is $-171M (high $-161M, low $-178M), average SG&A $1.04B (high $1.07B, low $1.01B), and average EPS is $-2.787 (high $-2.635, low $-2.913).

Did the RYTM's actual financial results beat the analysts' financial forecasts?

Based on Rhythm Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $77.43M, beating the average analysts forecast of $74.71M by 3.64%. Apple's EBITDA was $-184M, beating the average prediction of $-14.941M by 1133.89%. The company's net income was $-185M, beating the average estimation of $-181M by 1.88%. Apple's SG&A was $117.53M, missing the average forecast of $435.16M by -72.99%. Lastly, the company's EPS was $-0.0032, missing the average prediction of $-2.961 by -99.89%. In terms of the last quarterly report (Sep 2023), Rhythm Pharmaceuticals's revenue was $22.5M, beating the average analysts' forecast of $22.18M by 1.47%. The company's EBITDA was $-40.646M, beating the average prediction of $-4.436M by 816.36%. Rhythm Pharmaceuticals's net income was $-44.163M, missing the average estimation of $-45.303M by -2.52%. The company's SG&A was $30.48M, missing the average forecast of $129.19M by -76.41%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.74 by 2.70%